Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Irofulven second generation - Lantern Pharma

Next Previous
Drug Profile

Irofulven second generation - Lantern Pharma

Alternative Names: Hydroxymethylacylfulvene; Irofulven-2; Irofulven-second-generation-Lantern-Pharma; LP 184; STAR-001

Latest Information Update: 22 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of California, San Diego
  • Developer Lantern Pharma
  • Class Antineoplastics; Cyclopropanes; Indenes; Sesquiterpenes; Small molecules; Spiro compounds
  • Mechanism of Action Alkylating agents; Apoptosis stimulants; DNA synthesis inhibitors; RNA polymerase II inhibitors; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioma; Glioblastoma; Pancreatic cancer; Teratoma; Rhabdoid tumour
  • New Molecular Entity No

Highest Development Phases

  • Phase I Solid tumours
  • Preclinical Rhabdoid tumour

Most Recent Events

  • 18 Mar 2024 Lantern Pharma and Starlight plans a phase Ib/II trial for CNS cancer in the second half of 2024
  • 02 Jan 2024 Preclinical trials in Rhabdoid tumour in USA (Parenteral), prior to January 2024 (Lantern Pharma pipeline, January 2024)
  • 08 Nov 2023 Lantern files 4 new patent applications for LP 184 and LP 284 relating to breast, liver, and blood cancers and an additional application directed to lyophilized formulations of these molecules
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top